Clinuvel Pharmaceutical Forecast, price target & analysts
AUD10.17
0.99%
today
Australia,
Jun 26, 08:00 am CET
Clinuvel Pharmaceutical Target price 2025 - Analyst rating & recommendation
Powered by
Clinuvel Pharmaceutical Classifications & Recommendation:
Buy
100%
Clinuvel Pharmaceutical Price Target
| Target Price | AUD22.78 |
| Price | AUD10.19 |
| Potential |
123.55%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target Clinuvel Pharmaceutical 2026 .
The average Clinuvel Pharmaceutical target price is AUD22.78.
This is
123.55%
register free of charge
AUD23.56
131.21%
register free of charge
AUD22.00
115.90%
register free of charge
|
|
| A rating was issued by 2 analysts: 2 Analysts recommend Clinuvel Pharmaceutical to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2026 of
123.55%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million AUD | 95.50 | 100.30 |
| 16.14% | 5.03% | |
| EBITDA Margin | 59.13% | 51.56% |
| 0.36% | 12.80% |
2 Analysts have issued a sales forecast Clinuvel Pharmaceutical 2025 . The average Clinuvel Pharmaceutical sales estimate is
AUD100m
Unlock
5.14%
higher
Unlock
AUD101m
6.08%
Unlock
AUD99.4m
4.19%
Unlock
This results in the following potential growth metrics:
2 Analysts have issued an Clinuvel Pharmaceutical EBITDA forecast 2025. The average Clinuvel Pharmaceutical EBITDA estimate is
AUD51.7m
Unlock
8.45%
lower
Unlock
AUD52.2m
7.59%
Unlock
AUD51.2m
9.31%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 3.04 |
Current Clinuvel Pharmaceutical Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WILSONS |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| WILSONS |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Oct 02 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
WILSONS:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
WILSONS:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Oct 02 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
